Connect with us

coronavirus

Coronavirus: Commission signs contract for the supply of a monoclonal antibody treatment

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Commission has signed a joint procurement framework contract with the pharmaceutical company Eli Lilly for the supply of a monoclonal antibody treatment for coronavirus patients. This marks the latest development in this first portfolio of five promising therapeutics announced by the Commission under the EU COVID-19 Therapeutics Strategy in June 2021. The medicine is currently under rolling review by the European Medicines Agency. 18 member states have signed up to the joint procurement for the purchase of up to 220,000 treatments.

Health and Food Safety Commissioner Stella Kyriakides said: “Over 73% of the EU adult population is now fully vaccinated, and this rate will still increase. But vaccines cannot be our only response to COVID-19. People still continue to be infected and fall ill. We need to continue our work to prevent illness with vaccines and at the same time ensure that we can treat it with therapeutics. With today's signature, we conclude our third procurement and deliver on our commitment under the EU Therapeutics Strategy to facilitate access to state-of-the-art medicines for COVID-19 patients.”

While vaccination remains the strongest asset both against the virus and its variants, therapeutics play a critical role in the COVID-19 response. They help to save lives, speed up recovery time, reduce the length of hospitalisation and ultimately ease the burden of health care systems.

Advertisement

The product from Eli Lilly is a combination of two monoclonal antibodies (bamlanivimab and etesevimab) for the treatment of coronavirus patients who do not require oxygen but are at high risk of severe COVID-19. Monoclonal antibodies are proteins conceived in the laboratory that mimic the immune system's ability to fight the coronavirus. They fuse to the spike protein and thus block the virus's attachment to the human cells.

Under the EU Joint Procurement Agreement, the European Commission has concluded until now nearly 200 contracts for different medical countermeasures with a cumulative value of over €12 billion. Under the joint procurement framework contract concluded with Eli Lilly, member states can purchase the combination product bamlanivimab and etesevimab if and when needed, once it has received either a conditional marketing authorisation at EU level from the European Medicines Agency or an emergency use authorisation in the member state concerned.

Background

Advertisement

Today's joint procurement contract follows the contract signed with Roche for the product REGN-COV2, a combination of Casirivimab and Imdevimab, on 31 March 2021 and the contract with Glaxo Smith Kline on 27 July 2021 for the supply of sotrovimab (VIR-7831), developed in collaboration with VIR biotechnology.

The EU Strategy on COVID-19 Therapeutics, adopted on 6 May 2021, aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. It will also coordinate, scale-up and ensure that the EU acts together in ensuring access to therapeutics via joint procurements.

The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe's health systems. Focusing on the treatment of patients with COVID-19, the Strategy works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.

On 29 June 2021, the strategy delivered its first outcome, with the announcement of five candidate therapeutics that could soon be available to treat patients across the EU. The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorization by October 2021, the target set under the strategy, provided the final data demonstrate their safety, quality and efficacy.

Global co-operation on therapeutics is crucial and a key component of our strategy. The Commission is committed to working together with international partners on COVID-19 therapeutics and make them available globally. The Commission is also exploring how to support the enabling environment for manufacturing health products, while strengthening research capacity in partner countries around the globe.

More information

EU Therapeutics Strategy

Coronavirus response

Safe COVID-19 vaccines for Europeans

coronavirus

Commission proposes additional funding to support global vaccination and to respond to global emergencies

Published

on

The European Commission has proposed to amend the EU Budget 2021 to provide additional support to policy areas which need reinforcement in view of recent developments and additional needs. Concretely, this Draft Amending Budget 6 will help speed up global vaccinations. It will provide an additional €450 million to reach the €1.3 billion which are needed to secure an additional 200 million doses of vaccines against COVID-19 for low and middle-income countries through COVAX, as announced by President von der Leyen in her State of the Union speech. This Draft Amending Budget 6 also proposes reinforcing the EU Civil Protection Mechanism with €57.8m. The funds foreseen in the budget to address emergencies need to be increased to cover the costs of the response to the emergencies and natural disasters which occurred last summer, including repatriation flights for EU nationals based in Afghanistan, operations in Haiti following the recent earthquake and fighting forest fires in Europe. The Draft Amending Budget needs to be approved by the European Parliament and by EU member states in the Council. A Q&A with more information is available here.

Advertisement

Continue Reading

coronavirus

COVID-19 vaccination: MEPs call for EU and global solidarity

Published

on

The EU must continue its concerted efforts to fight the COVID-19 pandemic and take urgent measures to ramp up vaccines production to meet citizens’ expectations, MEPs say,  PLENARY SESSION ENVI.

In the plenary debate with the Portuguese Presidency and Commission President Ursula von der Leyen, MEPs commented on the state of play of the EU’s COVID-19 vaccination strategy.

Many members emphasized that the EU had made the right key decisions, especially on the collective European approach to vaccination and on standing up for its citizens’ rights by putting safety first and enforcing EU liability rules.

Advertisement

President von der Leyen defended the EU’s choice to order vaccines collectively, the need for global solidarity and the decision not to take any shortcuts on the safety and efficiency of vaccines. Lessons must be drawn from past mistakes, she acknowledged, as “we are still not where we want to be in the fight against the virus”.

Solutions to exit the crisis must be found in the spirit of solidarity, between member states as well as at global level, MEPs underlined. The EU has a responsibility for the rest of the world and must ensure vaccines are fairly distributed across the globe, they added, reiterating that “nobody is safe until everybody is safe”.

Members acknowledged that the EU underestimated the challenges of vaccine mass production and that concrete measures to ramp up production must now be taken as a matter of utmost priority. Many MEPs urged the Commission to enforce existing contracts and at the same time support member states in their vaccine deployment strategies.

Advertisement

In order to build citizens’ trust in the vaccination efforts and avoid disinformation, the EU must “tell the truth”, some MEPs pointed out. In this respect, many recalled the need for transparency with regard to contracts, as well as for comprehensive and clear data on vaccines rollout at national level.

Taking into account the large amounts of public money invested, several MEPs also called for increased parliamentary scrutiny of the implementation of the vaccines strategy.

Watch the video recording of the debate here. Click on the names below for individual statements.

Ana Paula Zacarias, Portuguese Presidency

Ursula von der Leyen, European Commission President (1st part2nd part3rd part)

Manfred Weber (EPP, DE)

Iratxe García Pérez (S&D, ES)

Dacian Cioloş (Renew Europe, RO)

Marco Zanni (ID, IT)

Ska Keller (Greens/EFA, DE)

Beata Szydło (ECR, PL)

Manon Aubry (The Left, FR)

Background

On 12 January 2021, MEPs quizzed the Commission on the latest developments regarding COVID-19 vaccines. A debate in plenary followed on 19 January focusing on the global EU strategy for COVID-19, while the Commission published an updated action plan to step up the fight against the pandemic on the same day.

During the plenary debate in January, MEPs expressed broad support for the common EU approach to fighting the pandemic and called for complete transparency regarding contracts and deployment of COVID-19 vaccines.

Further information

Continue Reading

coronavirus

EU envoy says Russia delays EMA Sputnik V vaccine inspections - media

Published

on

By

A health-care worker prepares a dose of Sputnik V (Gam-COVID-Vac) vaccine against the coronavirus disease (COVID-19) at a vaccination centre in Gostiny Dvor in Moscow, Russia July 6, 2021. REUTERS/Tatyana Makeyeva/File Photo

Russia has repeatedly delayed inspections by the European Medicines Agency (EMA) necessary for the certification of its Sputnik V COVID-19 vaccine in the European Union, the EU's ambassador to Moscow was quoted as saying on Friday (8 October), Reuters, write Olzhas Auyezov, Anton Zverev and Andrew Osborn in Moscow and Jo Mason in London.

The Sputnik V vaccine, widely used in Russia and approved for use in more than 70 countries, is undergoing a review by the World Health Organization and the EMA.

Advertisement

Russia has accused the West of refusing to certify its flagship vaccine for political reasons. Without EMA approval, it is harder for Russians to travel throughout the EU.

"This is a technical rather than a political process," EU ambassador Markus Ederer told Russia's RBC media outlet in an interview.

"When Russian officials talk about the process being delayed and politicised by the European side, I sometimes think they are largely referring to themselves because it is them who makes this about politics."

Advertisement

Russia’s sovereign wealth fund, the Russian Direct Investment Fund (RDIF), markets Sputnik V overseas. It declined to comment.

The EMA said it could not immediately comment on the matter.

Five people with knowledge of European efforts to assess the drug told Reuters earlier this year that the developers of Sputnik V had repeatedly failed to provide data that regulators deem to be standard requirements of the drug approval process. read more

RDIF said at the time that Reuters’ reporting contained “false and inaccurate statements” based on anonymous sources who were attempting to harm Sputnik V as part of a disinformation campaign.

Russian Health Minister Mikhail Murashko said this month that all the barriers to register Sputnik V with the WHO had been cleared and that only some paperwork remained to be completed. read more

The TASS news agency cited the health ministry as saying on Friday that EMA inspectors might carry out a visit to Russia in December.

Continue Reading
Advertisement
Advertisement
Advertisement

Trending